(Photo by Flickr user Luca Volpi, used under a Creative Commons license)
Personal Genome Diagnostics (PGDx) received a new contract from the U.S. Department of Veterans Affairs to provide a test for cancer that does not require tissue samples.
The Canton-based company makes a liquid biopsy, which tests for cancer by evaluating 64 genes that are associated with cancer.
The test can be conducted through a blood test, rather than obtaining tissue samples through a traditional biopsy or conducting an ultrasound. The test can also be conducted multiple times during treatment, providing a “real-time livestream of what’s happening at the genetic level in the patient’s tumor or tumors,” PGDx Manager for Translational Science and Diagnostics John Simmons told Technical.ly last year.
The test will be offered to advanced cancer patients who are receiving treatment in the VA, according to the company.
The company’s work on liquid biopsy got attention from the White House last year, when Vice President Joe Biden included PGDx among the group of experts working on the Cancer Moonshot.
The new contract is an expansion of work with the VA for PGDx, which was founded by Johns Hopkins researchers. PGDx also has a contract to provide its product which analyzes tumors on the genetic level.
The company raised a $21.4 million Series A in 2015.-30-
Fearless, SmartLogic team up on Challenge.gov development
This earmuff-style technology looks to make life less ruff for military working dogs
emocha and University of Maryland School of Pharmacy join forces on medication reviews
How independence fuels confidence and professional development at SmartLogic
These Maryland cyber startups got $1M contracts at an Air Force pitch day
Between Two Founders: Renalert talks scale after Beta City win
AvengerCon IV showed how U.S. Cyber Command is building community
How this lawyer is helping entrepreneurs bark up the right tree
Sign-up for daily news updates from Technical.ly Baltimore